Podcast: Play in new window | Download (Duration: 35:21 — 32.4MB) | Embed
Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | iHeartRadio | Blubrry | Podcast Index | TuneIn | Deezer | RSS | More
HOST: Hildy Grossman, CO-HOST: Jordan Rich
GUEST: Zachary Rogers, Ph.D. Postdoc at MIT | American Cancer Society Fellow
Lung cancer treatment is undergoing a revolution. In the last 15 years, we’ve transitioned from broad chemotherapy to precision medicine, targeting the specific genetic drivers of each patient’s cancer. This shift, along with the rise of immunotherapy, offers unprecedented hope. Today, we speak with Dr. Zachary Rogers, a post-doctoral researcher at MIT’s Koch Institute, whose work on ALK mutations illuminates these advancements. He’ll explain how targeted therapies and immunotherapies combat cancer, and delve into crucial questions: why do some patients respond while others don’t, and why does recurrence occur even after apparent remission? Dr. Rogers will also share insights into groundbreaking research on new cancer markers. Join us for a critical discussion on the future of lung cancer treatment – a conversation that provides a vital look at the forefront of cancer research.